Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elgene Lim

Showing results (71-80 of 130) with videos related to

Pageof 13
Sort By:
Nature Communications|August 26, 2021
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancerCarla L Alves, Sidse Ehmsen, Mikkel G Terp, et al.
Breast Cancer Research and Treatment|August 1, 2022
An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancerElgene Lim, Frances Boyle, Meena Okera, et al.
Genes & Development|January 7, 2015
A laminin 511 matrix is regulated by TAZ and functions as the ligand for the α6Bβ1 integrin to sustain breast cancer stem cellsCheng Chang, Hira Lal Goel, Huijie Gao, et al.
Nature Communications|September 17, 2021
Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancerCarla L Alves, Sidse Ehmsen, Mikkel G Terp, et al.
Science Translational Medicine|December 17, 2025
Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in <i>PIK3CA</i>-mutant breast cancerCarla L Alves, Leena Karimi, Mikkel G Terp, et al.
Molecular Systems Biology|February 11, 2026
Genetic barcoding uncovers the clonal makeup of solid and liquid biopsies and their ability to capture intra-tumoral heterogeneityAntonin Serrano, Tom S Weber, Jean Berthelet, et al.
Cancer Cell|September 14, 2013
Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cellsWai Leong Tam, Haihui Lu, Joyce Buikhuisen, et al.
Cancer Discovery|November 8, 2015
MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in MalignancyManish Neupane, Allison P Clark, Serena Landini, et al.
Nature Communications|March 13, 2026
ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancerAnn E Collier, Stephanie Hilz, Alejandro M Chibly, et al.
Breast Cancer Research : BCR|August 14, 2020
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancerNeil Portman, Heloisa H Milioli, Sarah Alexandrou, et al.
Pageof 13

Showing results (71-80 of 130) with videos related to

Sort By:
Pageof 13
Nature Communications|August 26, 2021
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancerCarla L Alves, Sidse Ehmsen, Mikkel G Terp, et al.
Breast Cancer Research and Treatment|August 1, 2022
An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancerElgene Lim, Frances Boyle, Meena Okera, et al.
Genes & Development|January 7, 2015
A laminin 511 matrix is regulated by TAZ and functions as the ligand for the α6Bβ1 integrin to sustain breast cancer stem cellsCheng Chang, Hira Lal Goel, Huijie Gao, et al.
Nature Communications|September 17, 2021
Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancerCarla L Alves, Sidse Ehmsen, Mikkel G Terp, et al.
Science Translational Medicine|December 17, 2025
Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in <i>PIK3CA</i>-mutant breast cancerCarla L Alves, Leena Karimi, Mikkel G Terp, et al.
Molecular Systems Biology|February 11, 2026
Genetic barcoding uncovers the clonal makeup of solid and liquid biopsies and their ability to capture intra-tumoral heterogeneityAntonin Serrano, Tom S Weber, Jean Berthelet, et al.
Cancer Cell|September 14, 2013
Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cellsWai Leong Tam, Haihui Lu, Joyce Buikhuisen, et al.
Cancer Discovery|November 8, 2015
MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in MalignancyManish Neupane, Allison P Clark, Serena Landini, et al.
Nature Communications|March 13, 2026
ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancerAnn E Collier, Stephanie Hilz, Alejandro M Chibly, et al.
Breast Cancer Research : BCR|August 14, 2020
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancerNeil Portman, Heloisa H Milioli, Sarah Alexandrou, et al.
Pageof 13